Get the Stockscreener App
78.35
1.50%
-1.19
After Hours:
78.35
Nuvalent Inc stock is traded at $78.35, with a volume of 401.07K.
It is down -1.50% in the last 24 hours and up +2.69% over the past month.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$79.54
Open:
$78.57
24h Volume:
401.07K
Relative Volume:
0.75
Market Cap:
$5.20B
Revenue:
-
Net Income/Loss:
$-224.29M
P/E Ratio:
-20.09
EPS:
-3.9
Net Cash Flow:
$-185.06M
1W Performance:
-4.54%
1M Performance:
+2.69%
6M Performance:
-8.69%
1Y Performance:
-1.99%
1-Day Range:
$77.41
$79.73
1-Week Range:
$76.18
$83.50
52-Week Range:
$55.53
$113.51
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
78.35 | 5.71B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-14-25 | Upgrade | UBS | Neutral → Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-24 | Initiated | UBS | Neutral |
| Aug-29-24 | Initiated | Barclays | Overweight |
| Apr-17-24 | Initiated | Jefferies | Buy |
| Apr-01-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
What institutional investors are buying Nuvalent Inc. stockSmart Portfolio Recommendation For Beginners - jammulinksnews.com
Why is Nuvalent Inc. stock attracting strong analyst attentionBest Dividend Report From AI Tools - jammulinksnews.com
Nuvalent Inc. stock outlook for YEARTechnical Stock Breakout Predictions Signal Entry Points - metal.it
Will Nuvalent Inc. Stock Benefit from AI and Green Energy TrendsFast Return Equity Trade Forecast Points to Small Caps - metal.it
Nuvalent Inc. Moves Into Overbought Range Analysts CautiousDay Trading Signals With High Precision Reviewed - metal.it
How high can Nuvalent Inc. stock price go in 2025AI Screening for Swing Trade Picks Finds Momentum - metal.it
Can Traders Expect Breakout From Nuvalent Inc. This WeekSmart Trade Plans With Risk Protection Explained - metal.it
How many analysts rate Nuvalent Inc. as a “Buy”Breakout Stocks Watchlist That Work - jammulinksnews.com
Should I hold or sell Nuvalent Inc. stock in 2025Capitalize on market momentum for maximum gains - jammulinksnews.com
How does Nuvalent Inc. compare to its industry peersAchieve breakthrough profits with smart strategies - jammulinksnews.com
What is the dividend policy of Nuvalent Inc. stockProven strategies for superior portfolio growth - jammulinksnews.com
How volatile is Nuvalent Inc. stock compared to the marketInvest confidently with real-time market updates - jammulinksnews.com
What are Nuvalent Inc. company’s key revenue driversHigh-velocity capital appreciation - jammulinksnews.com
Is Nuvalent Inc. a growth stock or a value stockAchieve consistent profits with proven methods - jammulinksnews.com
What are analysts’ price targets for Nuvalent Inc. in the next 12 monthsInvest confidently with proven investment plans - jammulinksnews.com
What markets is Nuvalent Inc. expanding into Is ISPO stock a good long term investment optionExceptional ROI - jammulinksnews.com
Key External Factors That Drive Nuvalent Inc. Stock Price MovementsHigh Reward Swing Trades - metal.it
What makes Nuvalent Inc. stock price move sharplyTargeted 200 Percent Gain - metal.it
Is Nuvalent Inc. a good long term investmentFree Stock Selection - PrintWeekIndia
Nuvalent Doses First Patient in Phase 3 ALKAZAR Trial for Neladalkib in ALK-Positive NSCLC - Insider Monkey
What analysts say about Nuvalent Inc. stockExplosive earnings growth - PrintWeekIndia
What institutions are buying Nuvalent Inc. stock nowSky-high return potential - jammulinksnews.com
Nuvalent Inc. Stock Analysis and ForecastHigh-yield capital appreciation - Autocar Professional
What drives Nuvalent Inc. stock priceConsistent triple returns - Autocar Professional
Nuvalent Initiates Phase 3 ALKAZAR Trial of Neladalkib in NSCLC - Pharmacy Times
Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC - The Malaysian Reserve
Nuvalent’s Accelerated ALKAZAR Trial Progress and Strong Financials Justify Buy Rating - TipRanks
Nuvalent begins Phase 3 trial of neladalkib in ALK-positive lung cancer - Investing.com
Nuvalent begins Phase 3 trial of neladalkib in ALK-positive lung cancer By Investing.com - Investing.com South Africa
Nuvalent Initiates Phase 3 ALKAZAR Clinical Trial - TipRanks
Nuvalent doses first patient in phase 3 lung cancer drug trial By Investing.com - Investing.com South Africa
Nuvalent doses first patient in phase 3 lung cancer drug trial - Investing.com India
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):